[Infostock Daily= Reporter Park Sang-In] Chong Kun Dang announced on the 31st that its operating profit for the second quarter of 2020 was 36.3 billion won, up 90.9% from the same period last year.
According to this report, Chong Kun Dang improved its sales and operating profit in the second quarter of this year despite the pandemic of new coronavirus infections(COVID-19).
Sales of specialty medicines such as diabetes treatment and hyperlipidemia treatment, which are the main products, have also steadily increased. In the second quarter of this year, prescriptions such as 'Atozet' for hyperlipidemia, 'Imotun' for arthritis, and 'Telminuvo' for hypertension treatment increased year-on-year.
In particular, these products are limited to the field of chronic diseases, which are the drugs that patients should take periodically. This is one of the reasons why sales impact from COVID-19 may not be significant.
In the third quarter, the final results of the European 2a phase of the autoimmune disease treatment 'CKD-506' will be announced. In the second half of the year, clinical trials are also underway in combination with the treatment of colorectal cancer 'CKD-516' and AstraZeneca anticancer drug 'Imfinzi'.
Reporter Park Sang-In si2020@infostock.co.kr
